Table 1.
Baseline Characteristics of the Participants*
| No Exercise
|
Exercise
|
P Value | |||
|---|---|---|---|---|---|
| Placebo (n = 14) | Testosterone (n = 17) | Placebo (n = 15) | Testosterone (n = 15) | ||
| Age, y | 41.8 (2.5) | 40.8 (1.2) | 44.4 (3.0) | 40.2 (2.2) | .59 |
|
| |||||
| Height, cm | 177.8 (2.9) | 176.3 (2.5) | 176.2 (1.9) | 172.6 (2.1) | .52 |
|
| |||||
| Weight, kg | 76.7 (3.2) | 77.1 (3.5) | 71.9 (2.9) | 69.1 (3.4) | .28 |
|
| |||||
| Body mass index, kg/m2 | 24.3 (0.9) | 25.0 (1.4) | 23.2 (1.1) | 23.2 (1.1) | .66 |
|
| |||||
| Serum testosterone levels, nmol/L† | 6.1 (0.7) | 7.1 (0.8) | 7.0 (1.0) | 7.0 (1.2) | .94 |
|
| |||||
| CD4+ cell count, ×106/L | 279 (93) | 357 (85) | 229 (56) | 340 (95) | .77 |
|
| |||||
| CD8+ cell count, ×106/L | 897 (89) | 872 (92) | 842 (136) | 669 (126) | .49 |
|
| |||||
| Weight loss, kg | 6.4 (2.0) | 7.4 (1.1) | 7.1 (1.1) | 6.7 (1.1) | .97 |
|
| |||||
| Antiretroviral therapy, % | 100 | 93 | 82 | 89 | .78 |
|
| |||||
| Protease inhibitors, % | 40 | 60 | 45 | 55 | .68 |
*
All data are presented as mean (SEM) unless otherwise indicated.
†
To convert serum testosterone levels to nanograms per deciliter, multiply by 28.843.